Panacea Biotec Pharma Limited - Due diligence report

A 360° intelligence report on Panacea Biotec Pharma Limited: trust score, financial health, credit view, compliance, directors, growth and d…

2019-03-22 New Delhi, Delhi Active Unlisted
Share
Connect MCP
PB Panacea Biotec Pharma Limited
Full Due-Diligence Report + Documents
  • Unlock all financial figures & 5-year trends
  • Full trust, health & credit-risk scores
  • Director details, charges & MCA documents
₹700 ₹449 Save ₹251 excl. GST
Or from ₹279/report with credits View credit packages
Company Credits – Starter
  • One credit unlocks this full due-diligence report
  • Use across any company’s report, anytime
  • Credits valid for 12 months
× ₹700 ₹279 = ₹2,790 60% off
Choose your own credit amount View credit packages

Panacea Biotec Pharma Limited — 360° Intelligence Report

Generated from MCA filings & public records
80/100
Trust Score
Low Risk

Panacea Biotec Pharma Limited is assessed as Low Risk with a Trust Score of 80/100. Panacea Biotec Pharma Limited is an active public limited indian non-government company incorporated in 2019, operating in the Pharma sector. The company has shown revenue growth across its recent filed years. It was profitable in its latest filed year. Based on MCA filings and public records, it currently shows a low compliance risk and moderate financial risk profile.

Report generated on 27 Jul 2026 from the latest processed filings. Panacea Biotec Pharma Limited snapshot & full profile →

Financial Health › Strong
Overall Assessment CautionWeakNeutralGoodStrong Strong
Compliance › Strong

Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.

02

Score Card

Higher is safer · rule-based & explainable
Trust ScoreLow Risk
80/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreLow Risk
86/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreModerate
70/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreModerate
60/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreLow Risk
85/100
Board strength, DIN status, churn and network.
Growth ScoreLow Risk
75/100
Revenue, profit, asset and hiring momentum.
Distress ScoreLow Risk
75/100
Early-warning signals - higher means fewer warnings.
03

Financial Intelligence Dashboard

Standalone · 4 filed year(s)

Unlock the full 5-year financial dashboard with charts and year-wise figures.

Get full access

Scores and observations on this page are already computed from the real filings - only the underlying figures are locked.

04

Credit & Compliance Intelligence

Why the scores are what they are
Credit Risk Score: 60/100 Moderate
  • Negative operating earnings - debt service depends on external support.
  • No open charges - unencumbered balance sheet.
  • Working-capital cover adequate.
  • Profitable - internal accruals available.

Charges position: 0 open (-) · 2 satisfied (1,618.44 cr).

Banking relationships (from registered charges)
LenderChargesAmount
Others2 48.0 cr
Compliance Score: 86/100 Low Risk
  • Company status is Active as per MCA.
  • Annual filings current (balance sheet Mar 2025).
  • Litigation present in 2 court forum(s).
  • 21 active GST registration(s).
Legal cases on record (2)
05

Director Intelligence

Stability score: 85/100
NameDIN / PANDesignationAppointedTenureDIN status
ANKESH JAIN 01234567 Director 01/04/2018 6 yrs Approved
Rajesh Jain 01234567 Director 01/04/2018 6 yrs Approved
MANJULA UPADHYAY 01234567 Director 01/04/2018 6 yrs Approved
NAROTAM KUMAR JUNEJA 01234567 Director 01/04/2018 6 yrs Approved
RAJESH JAIN 01234567 Director 01/04/2018 6 yrs Approved
Sanjay Trehan 01234567 Director 01/04/2018 6 yrs Approved
  • 6 directors on the board.
  • No disqualified or deactivated DINs.
  • 3 director exit(s) in the last 3 years.
Director & KMP remuneration (FY 2023)
NameDesignationTotal remuneration
A K SharmaManaging Director2.4 cr
R MehtaWhole-time Director1.6 cr
S IyerCFO95.0 L

Remuneration is disclosed in the latest annual return. Unlock full report

06

Ownership & Group Intelligence

As per FY 2023 annual return
Promoter holding
64.27%
Public / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
Panacea Biotec Limited
Subsidiaries
-
Group entities
-
Capital events
4 allotment(s) · 0 transfer(s)

Promoters hold a dominant controlling stake - exact percentages are part of the full report.

Group entityRelationship% held
Panacea Biotec Limited Holding Company 74.00%

Key managerial personnel: ANKESH JAIN (Whole-time director) · NAROTAM KUMAR JUNEJA (Whole-time director) · RAJESH JAIN (Managing Director) · Sanjay Trehan (Whole-time director)

Full shareholding pattern, group structure & capital events →

07

Risk Intelligence Center

Growth 75 · Distress 75
Growth signals & trust indicators
Revenue acceleration: +38% over 3 year(s).
EPFO headcount growing - hiring signal.
Operating for 7 years.
Active EPFO - real payroll on record.
Active GST registration(s).
Distress signals & risk flags
Revenue declined year-on-year.
2 court case(s) on record - see the legal section for details.
08

Stakeholder Verdicts

Vendor · Banker · Investor
Vendor due diligence81/100
Favourable indicators
Suitability as a supplier / customer counterparty.
  • Statutory record is clean.
  • 1 distress signal(s) - see Risk Center.
  • Financial filings available for verification.
Banker assessment70/100
Favourable lending indicators
Indicative lending comfort for banks, NBFCs and trade credit.
  • Debt capacity assessed from filed statements.
  • No existing security registered - first-charge position available.
  • Compliance record supports lending.
Investor view74/100
Positive growth indicators
Growth quality and scalability through an investor lens.
  • 2 growth signal(s) detected.
  • Margin and return trends computable from filings.
  • Management team looks stable.
09

MCA Filings & Events Timeline

Latest 15 events
29 Sep 2025
Last AGM held
Annual general meeting
31 Mar 2025
Latest balance sheet
Filed with ROC
13 Feb 2025
Director appointed
Sanjay Trehan (Whole-time director)
Director ceased
Sanjay Trehan
05 Dec 2024
Director ceased
Rajesh Jain
12 Nov 2024
Director appointed
Rajesh Jain (Director)
31 May 2024
Director ceased
ANKESH JAIN
01 Apr 2022
Director appointed
NAROTAM KUMAR JUNEJA (Whole-time director)
Director ceased
NAROTAM KUMAR JUNEJA
03 Mar 2022
Charge satisfied
Others
30 Jul 2021
Director ceased
MANJULA UPADHYAY
23 Jul 2021
Director appointed
MANJULA UPADHYAY (Director)
11 Dec 2020
Director ceased
KRISHNA MURARI LAL
Director ceased
DEEPAK SHAMSUNDER KANVINDE
10 Dec 2020
Director ceased
SHANTANU YESHWANT NALAVADI
10

Key Observations

Auto-generated from the data above
Revenue grew 1.42 over the last 3 financial year(s).
Net profit margin moved from 2.1x to 24%.
Net worth is positive.
Compliance record is strong - status, filings and flags are clean.
6 active director(s) / partner(s); board looks stable and experienced.
21 active GST registration(s) indicate ongoing business operations.
All 2 registered charge(s) stand satisfied - past borrowings repaid.
EPFO-registered employer - verifiable payroll history exists.
Promoters hold a dominant controlling stake as per the FY 2023 annual return.
Director / KMP remuneration is disclosed in the latest annual return - exact figures available in the full report.
Capital has been raised through 4 security allotment(s) - amounts available in the full report.
1 overseas direct investment(s) (ODI) on record - international footprint.
11

Peers & Related Companies

Full peer comparison →
CompanyCINLocation
Pretty Petals Private Limited U51397DL2012PTC229627 New Delhi, Delhi, India
Caplinpoint U24304TN2018PLC126270 Chennai, Tamil Nadu, India
Mosaic Wellness U52609MH2019PTC328779 Thane, Maharashtra, India
Msn Organics Private Limited U24110TG2006PTC051858 Hyderabad, Telangana, India
Threton Healthcare Private Limited U74999MH2014PTC257981 Mumbai, Maharashtra, India
Narayan Organics Pvt Ltd U24110GJ1992PTC017951 Ahmedabad, Gujarat, India
Universal Chemicals And Industries Private Limited U99999MH1961PTC012229 Mumbai, Maharashtra, India
Mg Shahani And Co Delhi U74899DL1948PTC001454 Delhi, Delhi, India
12

Who Uses This Report

CA · CS · Banker · Investor · Vendor
Chartered Accountants (CA)

Verify Panacea Biotec Pharma Limited before audits and certifications: compliance score 86/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.

Company Secretaries (CS)

Track statutory health of Panacea Biotec Pharma Limited: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.

Bankers & NBFCs

Current banker verdict: Favourable lending indicators. Credit risk score 60/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.

Investors & Analysts

Investor view: Positive growth indicators. Growth score 75/100, margin trends, ownership structure and peer set for Panacea Biotec Pharma Limited - screening before a deeper diligence.

Vendors & Procurement Teams

Vendor verdict: Favourable indicators. Trust score 80/100, distress signals and MSME payment-delay disclosures - know whether Panacea Biotec Pharma Limited pays its suppliers before you extend credit terms.

Lawyers & Compliance Teams

Litigation footprint (2 case(s) on record), regulatory flags, charge documents trail and director networks for Panacea Biotec Pharma Limited - groundwork for KYC, onboarding and disputes.

13

Frequently Asked Questions

Is Panacea Biotec Pharma Limited an active company?

Panacea Biotec Pharma Limited has MCA status “Active” with a compliance score of 86/100 (Low Risk).

Is Panacea Biotec Pharma Limited financially healthy?

Panacea Biotec Pharma Limited has a Financial Health Score of 70/100 (Moderate) based on its filed financial statements.

Should I do business with Panacea Biotec Pharma Limited?

Its overall Trust Score is 80/100 (Low Risk). Vendor verdict: Favourable indicators. Review the risk flags in the Risk Intelligence Center before deciding.

Who controls Panacea Biotec Pharma Limited?

The ultimate holding entity is Panacea Biotec Limited. 6 active director(s) are on record.

Does Panacea Biotec Pharma Limited have loans or charges against its assets?

No open charges - all 2 registered charge(s) stand satisfied, indicating past borrowings were repaid.

Is Panacea Biotec Pharma Limited up to date with its ROC filings?

Annual filings current (balance sheet Mar 2025). Overall compliance score: 86/100 (Low Risk).

Is it risky to lend to Panacea Biotec Pharma Limited?

Its Credit Risk Score is 60/100 (Moderate). Banker verdict: Favourable lending indicators.

Disclaimer: This report is generated automatically from MCA filings and public records as available in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice. Verify from official sources and consult a qualified professional before any business, lending or investment decision. If you represent this company and believe any information is inaccurate or outdated, report it here and we will review promptly.